John Libbey Eurotext



End-of-life platelet transfusion in haematological malignancies: a review Ahead of print


1 Service d’hématologie, Besançon University Hospital, France
2 Centre d’investigation clinique, Inserm CIC1431, Besançon University Hospital, Besançon, France
3 Etablissement français du sang, Bourgogne Franche-Comté, Dijon, France
4 Laboratoire de neurosciences intégratives et cliniques EA481, University Bourgogne Franche-Comté, Besançon, France
5 Service de soins palliatifs, Besançon University Hospital, France
* Off-prints

One of the specificities and complexities of palliative care in haematology is the issue of platelet transfusion. Platelet concentrates constitute a particular kind of transfusion product. Debate is ongoing about their utilisation and some transfusion parameters even outside the end-of-life context. This debate is exacerbated in patients also can be young patients when quality of life takes precedence. Moreover, the number of allocated platelet concentrates every year continues to increase, making their optimal use crucial. The information currently available is insufficient to reach a consensus over their use at the end of life. This review of articles published after 2011 aims to contribute towards both the practical and ethical aspects of this debate.

What do you want to do ?
New mail